Natco Pharma Limited — Important, 12-02-2025: Financial Result Updates

NATCO Pharma Limited reported consolidated total revenue of ₹651.1 Crore for the third quarter of FY2025, a decline from ₹795.6 Crore in the same quarter last year. The net profit for the period was ₹132.4 Crore, compared to ₹212.7 Crore in the previous year, indicating the impact of reduced contribution from export formulations.

The revenue decrease can be attributed to a significant drop in the formulation export business, which fell to ₹285.8 Crore from ₹605.6 Crore year-over-year. However, the domestic formulations segment remained relatively stable at ₹96.1 Crore, supported by ongoing market demand. The company anticipates a rebound in growth in the coming quarters with an expected recovery in the export sector.

Operational costs declined slightly, reflecting cost management initiatives despite the downturn in revenues. The earnings per share (EPS) for the quarter stood at ₹7.43.

The company declared a third interim dividend of ₹1.5 per equity share, reaffirming its commitment to returning value to shareholders even amid challenging market conditions.

Investors may consider holding their positions as the company navigates current headwinds but appears to be positioned for future growth with potential stability anticipated in both domestic and international markets.